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Background: The angiotensin receptor antagonist fimasartan lowered blood pressure (BP) in a 
previous large population study. The purpose of this study was to evaluate whether fimasartan 
treatment for 3 months affects clinical and home BP variability in addition to reducing BP.
Methods: The study enrolled 1,396 patients (mean age 56.2±10.0 years; males 53.6%) with 
mild-to-moderate hypertension who had a complete set of home BP measurements (morning 
and evening) and metabolic risk evaluation. During the 3 months of study, fimasartan alone 
was used to control BP at a daily dose of 30–120 mg. Clinical and home BP measurements 
were performed before and after the 3-month treatment. BP variability included beat-to-beat 
variability (clinical) and day-to-day variability (home).
Results: Fimasartan reduced BP after 3 months of treatment. The average reduction of clinical 
systolic BP (c-SBP) was 15.08±18.36 mmHg (P,0.0001), and the average reduction of morning 
home SBP (m-SBP) was 11.49±19.33 mmHg (P,0.0001). Beat-to-beat variability as standard 
deviation (SD) of c-SBP was reduced from 4.56±3.22 to 4.24±3.11 mmHg (P=0.0026). Day-to-
day variability as SD of m-SBP was reduced from 7.92±6.74 to 6.95±4.97 mmHg (P,0.0001). 
Multiple regression analysis revealed an independent association between the change in the 
SD of c-SBP and the change in c-SBP (P=0.0268) and, similarly, between the change in the 
SD of m-SBP and the change in m-SBP (P=0.0258), after adjusting for age, sex, body mass 
index, and change in mean BP.
Conclusion: This study indicated that 3 months of fimasartan treatment reduced day-to-day 
BP variability independent of BP reduction in patients with hypertension.
Keywords: angiotensin receptor blockers, hypertension, blood pressure variability
Introduction
Blood pressure (BP) measured in the clinic does not provide comprehensive information 
about an individual’s BP profile and may be of limited prognostic value, thus requiring 
out-of-office BP monitoring.1,2 Home BP can be measured repeatedly in the comfort 
of the patient’s own home in a relaxing environment, which provides information 
about day-to-day BP variability (BPV) and enables a more accurate understanding of 
a subject’s BP profile. Home BP has been widely accepted as a useful tool for clinical 
management of patients with hypertension and cardiovascular disease.
BP is characterized by marked temporal fluctuations showing beat-to-beat 
variability, 24-hour variability, day-to-day variability, and visit-to-visit variability. 
Clinically, BPV is a well-known risk factor for cardiovascular events and is associ-
ated with target organ damage and all-cause mortality that is independent of office 
BP levels.3–8 Beat-to-beat variability or 24-hour variability reflects increases in central 
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sympathetic drive, decreases in arterial or cardiopulmonary 
reflex, and increases in arterial stiffness.9,10 Humoral, rheo-
logical, and emotional factors and behavioral influences also 
can be involved in BPV. By contrast, day-to-day variability 
or visit-to-visit variability is proposed to be due to increased 
arterial stiffness, improper dosing or titration of antihyperten-
sive medication, poor medication compliance, and seasonal 
variations in BP.11,12
Day-to-day BPV is independent of beat-to-beat BPV and 
may have significantly different effects on hypertension prog-
nosis. Recent studies show that increased day-to-day home 
BPV is associated with cardiovascular risk, severity of target 
organ damage in patients with hypertension13 or diabetes 
mellitus,14 and cardiovascular mortality in a community-
dwelling population.15 In the Anglo-Scandinavian Cardiac 
Outcomes Trial-Blood Pressure-Lowering Arm trial, visit-
to-visit systolic BPV during treatment was a strong predictor 
of stroke and coronary events independent of mean levels 
of clinical or ambulatory systolic BP (SBP) in patients with 
hypertension.16 Therefore, reducing both BPV and mean BP 
has been recognized as a potential target for improved man-
agement of hypertension to prevent cardiovascular events, 
particularly stroke.6,16
Several small-scale and heterogeneous human studies 
on the effects of antihypertensive drugs report conflicting 
results. Calcium channel blockers such as amlodipine, but 
not beta-blockers, confer favorable effects to decrease home 
BPV.17 Other studies reported increased home BPV after 
treatment with beta-blockers.18,19 Inconsistent results also 
were observed even within the same class of antihyperten-
sive medication, such as angiotensin II receptor blockers 
(ARBs).20–22
Fimasartan is an ARB that effectively and safely reduced 
high BP in the Safe-KanArb study.23 However, its effect on 
reducing BPV has not yet been determined. The objective 
of the present study was to determine whether fimasartan 
reduced BPV in the clinic and at home after 3 months of 
treatment in hypertensive patients with low-to-moderate 
cardiovascular risk.
Methods
This investigation is part of the K-MetS Study, which is a 
prospective, multicenter, single-arm, observational study. 
The study design, socioeconomic and demographic charac-
teristics of the study, and project details have been described 
in our previous article.24 This study was approved by the 
Institutional Review Board Committee at the Cheil General 
Hospital, on behalf of 582 primary care clinics. Another 
ten university hospitals in South Korea approved this study 
through their own Institutional Review Board committees. 
Informed consent was obtained from all study subjects.
study population
A total of 10,601 hypertensive patients from 582 primary 
clinics and eleven university hospitals were enrolled between 
October 17, 2011 and October 31, 2012. Patients were 
required to meet the following inclusion criteria: 1) diagnosed 
with hypertension, at least 20 years old, and intend to use 
fimasartan; 2) agree to participate in the study and sign the 
informed consent form; and 3) maintain a fasting state at each 
visit. Patients who were treated with fimasartan at baseline 
were excluded.24 Finally, 1,396 patients were enrolled who 
were treated with fimasartan at a daily dose of 30–120 mg 
for 3 months, completed the 3-month follow-up visits, and 
scheduled BP measurements. Patients were enrolled in three 
different groups: naïve, switch, and add-on. In naïve group, 
patients had no previous antihypertensive medication and 
received fimasartan. In switch group, patients were switched 
from other antihypertensive drug in the baseline to fimasartan 
and in an add-on group, patients who received antihyperten-
sive drug also received fimasartan as an add-on therapy.
BP measurement
The Omron HEM-7220 and the Omron HEM-7200 (both 
Omron, Tokyo, Japan) were used to measure BP in the clinic 
and at home, respectively.25 These are upper-arm cuff devices 
based on the cuff automated-oscillometric principle. Clinical 
BP measurements were performed under standardized condi-
tions (in the same arm by the same physician or nurse). The 
study participants were educated about self-measurement 
of BP at home. They were instructed to measure their BP 
in the morning and evening. An average of two or more 
BP readings at 2-minute intervals from the same arm was 
recorded in the morning and evening for 7 consecutive days. 
Morning BP was measured within 1 hour of waking, after 
urination, in the sitting position, after resting for 5 minutes, 
and before taking medications or eating. In the evening, BP 
was measured before going to bed, after resting for 5 minutes, 
and in the sitting position. An average of 6 days of record-
ings from the 2nd to the 7th day was used for the analysis. 
Baseline assessment included a health questionnaire and 
BP measurements and was conducted before and after the 
3-month treatment with fimasartan.24 Clinical BPV, which 
measures beat-to-beat variability, was defined as the standard 
deviation (SD) of clinical systolic BP (c-SBP) measured three 
times at 2-minute intervals. Home BPV, which represents 
day-to-day BPV, was defined as the SD of morning home 
systolic BP (m-SBP).
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Data analysis
The baseline characteristics of the study subjects were 
compared between sexes using the χ2 test for dichotomous 
variables or the independent t-test for continuous variables. 
Differences between measured variables (eg, BP) were 
examined using the paired t-test between baseline and after 
3 months of follow-up. We analyzed males and females 
separately because sex may affect BPV.26 To evaluate the 
potential factors associated with clinical or home SBP vari-
ability, both simple and multiple linear regression analyses 
were conducted. Multiple linear regression models included 
potential factors such as clinical or home average SBP and 
diastolic BP (DBP), sex, age, history of cardiovascular 
disease, and smoking. This was done because most of these 
factors have a positive relationship with BPV, in part due to 
the stiffening influence on large- and medium-sized arteries, 
with an increase in the pressure excursions within the arterial 
compartment. All analyses were performed using SAS 9.3 
(SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics
Baseline demographic and clinical characteristics of the 
participants are presented in Table 1. A total of 1,396 par-
ticipants were enrolled; the mean age was 56.17±10.0 years; 
17.55% had diabetes, 6.88% had ischemic heart disease, and 
0.93% had stroke.
changes in BP during the study
At baseline, the mean c-SBP and clinical DBP levels were 
142.39±17.00 and 88.03±11.35 mmHg, respectively. 
These values were significantly reduced to 127.32±13.14 
and 79.37±9.40 mmHg (P,0.0001 for both), respec-
tively, after 3 months of fimasartan treatment (Table 2). 
m-SBP and morning home DBP levels were 138.80±19.81 
and 83.26±13.16 mmHg, respectively; these were sig-
nificantly reduced after 3 months of fimasartan treatment to 
127.32±16.72 and 76.62±11.32 mmHg (P,0.0001 for both), 
respectively. The same pattern was observed for evening 
home SBP (e-SBP) and evening home DBP after 3 months 
of fimasartan treatment; e-SBP was 137.57±20.53 mmHg and 
declined to 126.33±17.06 mmHg, and evening home DBP 
was 81.35±13.29 mmHg and declined to 75.07±11.44 mmHg 
(P,0.0001 for both).
changes in BPV during the study
At baseline, the SDs of c-SBP and clinical DBP were 
4.56±3.22 and 3.19±2.45 mmHg, respectively (Table 3). 
After 3 months of fimasartan treatment, the SDs of c-SBP 
and DBP were significantly reduced to 4.24±3.11 mmHg 
(P=0.0026) and 2.94±2.20 mmHg (P=0.0024), respectively. 
The SDs of m-SBP and morning home DBP also showed 
significant reduction from 7.92±6.74 and 5.30±3.98 mmHg to 
6.95±4.97 and 4.83±3.23 mmHg (P,0.0001 and P=0.0002), 
respectively. The same trend was observed for the SDs of 
evening home SBP and DBP; SD of e-SBP declined from 
8.39±6.94 to 7.16±5.38 mmHg (P,0.0001), and SD of eve-
ning home DBP declined from 5.80±4.13 to 5.16±3.32 mmHg 
(P,0.0001). Figure 1 shows that the correlation between the 
SD of c-SBP and the SD of m-SBP was weak at baseline and 
then became stronger after 3 months of fimasartan treatment. 
The same pattern was observed for the SD of c-SBP and 
Table 1 Baseline characteristics of the study population
All
(N=1,396)
Male
(N=748)
Female
(N=648)
P-value*
age, mean ± sD (years) 56.17±10.00 55.47 56.98 0.0042
Body weight (kg), mean ± sD and mean 67.41±11.11 72.52 61.52 ,0.0001
height (cm) 162.91 168.80 156.11 ,0.0001
Body mass index (kg/m2) 25.32 25.42 25.21 0.2291
current smoking, n (%) 249 (17.84) 231 (30.88) 18 (2.78) ,0.0001
Family history of cVD, n (%) 261 (18.70) 137 (18.32) 124 (19.14) 0.9239
history of hypertension (years) 4.13 4.23 4.02 0.4515
Duration of antihypertensive drug use (years) 3.87 3.92 3.80 0.6227
current antihypertensive drug use, n (%) 946 (67.77) 516 (68.98) 430 (66.36) 0.2951
Diabetes, n (%) 245 (17.55) 150 (20.05) 95 (14.66) 0.0082
ischemic heart disease, n (%) 96 (6.88) 54 (7.22) 42 (6.48) 0.5870
stroke, n (%) 13 (0.93) 9 (1.20) 4 (0.62) 0.2807
Treatment type
naïve,a n (%) 450 (32.23) 232 (31.02) 218 (33.64) 0.0035
switch,b n (%) 597 (42.77) 302 (40.37) 295 (45.52) –
add-on,c n (%) 349 (25.00) 214 (28.61) 135 (20.83) –
Notes: *P-value between male and female. aPatients without previous antihypertensive medication who received fimasartan. bPatients who were switched from other 
antihypertensive drug to fimasartan. cPatients who received fimasartan as an add-on antihypertensive therapy.
Abbreviation: cVD, cardiovascular disease.
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Table 2 Changes in BP and heart rate after fimasartan treatment
Baseline 3 months Difference P-value
Clinical BP, mean ± SD
c-sBP (mmhg) 142.39±17.00 127.32±13.14 15.08±18.36 ,0.0001
c-DBP (mmhg) 88.03±11.35 79.37±9.40 8.66±11.38 ,0.0001
c-heart rate (bpm) 72.08±10.04 71.68±9.64 0.40±9.30 0.1055
Home BP, mean ± SD
m-sBP (mmhg) 138.80±19.81 127.32±16.72 11.49±19.33 ,0.0001
m-DBP (mmhg) 83.26±13.16 76.62±11.32 6.64±11.98 ,0.0001
m-heart rate (bpm) 71.91±11.25 71.86±10.86 0.15±9.91 0.5866
e-sBP (mmhg) 137.57±20.53 126.33±17.06 11.18±19.73 ,0.0001
e-DBP (mmhg) 81.35±13.29 75.07±11.44 6.31±12.28 ,0.0001
e-heart rate (bpm) 73.81±11.59 73.25±11.17 0.66±10.12 0.0184
Abbreviations: BP, blood pressure; bpm, beats per minute; c, clinical; DBP, diastolic blood pressure; e, evening; m, morning; sBP, systolic blood pressure.
Table 3 Changes in BP variability SD after fimasartan treatment
Variable Baseline 3 months Difference P-value
SD of beat-to-beat BP in clinic, mean ± SD
sD of c-sBP (mmhg) 4.56±3.22 4.24±3.11 0.33±4.05 0.0026
sD of c-DBP (mmhg) 3.19±2.45 2.94±2.20 0.25±3.13 0.0024
SD of day-to-day BP at home, mean ± SD
sD of m-sBP (mmhg) 7.92±6.74 6.95±4.97 0.97±7.31 ,0.0001
sD of m-DBP (mmhg) 5.30±3.98 4.83±3.23 0.47±4.67 0.0002
sD of e-sBP (mmhg) 8.39±6.94 7.16±5.38 1.16±6.89 ,0.0001
sD of e-DBP (mmhg) 5.80±4.13 5.16±3.32 0.59±4.38 ,0.0001
Abbreviations: BP, blood pressure; c, clinical; DBP, diastolic blood pressure; e, evening; m, morning; sBP, systolic blood pressure; sD, standard deviation.
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Figure 1 Correlation between standard deviation (sd) of clinical systolic blood pressure (SBP) and sd of morning home SBP at baseline and after 3 months of fimasartan 
treatment.
Notes: (A) sd of morning home sBP versus sd of clinical sBP at baseline. (B) sd of morning home SBP versus sd of clinical SBP after fimasartan treatment. (C) sd of evening 
home sBP versus sd of clinical sBP at baseline. (D) sd of evening home SBP versus sd of clinical SBP after fimasartan treatment.
Abbreviations: b_SBPsd, sd of baseline SBP; m3_SBPsd, sd of clinical SBP after 3 months of fimasartan treatment; b_am_hSBPsd, sd of baseline morning home SBP; 
b_pm_hsBPsd, sd of baseline evening home sBP.
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Table 4 linear regression analyses of factors associated with sD of clinical and home sBP at baseline
SD of clinical SBP SD of morning home SBP
Simple regression Multiple regression Simple regression Multiple regression
β (SE) P-value β (SE) P-value β (SE) P-value β (SE) P-value
age (years) 0.02 (0.01) 0.0061 0.02 (0.01) 0.0065 0.05 (0.02) 0.0067 0.06 (0.02) 0.0005
sex (females vs males [ref]) 0.14 (0.17) 0.4133 0.16 (0.22) 0.4737 1.07 (0.36) 0.0032 1.76 (0.44) ,0.0001
BMi (kg/m2) 0.02 (0.03) 0.5668 0.01 (0.03) 0.6156 0.13 (0.06) 0.0246 0.10 (0.05) 0.0553
smoking (current vs nonsmoker) −0.26 (0.23) 0.2609 −0.20 (0.26) 0.4359 −0.06 (0.48) 0.9012 0.33 (0.51) 0.5172
smoking (ex-smoker vs nonsmoker) −0.17 (0.28) 0.5479 −0.20 (0.31) 0.5102 −0.52 (0.58) 0.3732 0.21 (0.61) 0.7287
alcohol intake (vs no alcohol intake) −0.05 (0.17) 0.7578 0.19 (0.21) 0.3635 −0.53 (0.36) 0.1421 0.30 (0.41) 0.4631
Diabetes 0.01 (0.23) 0.9616 −0.05 (0.23) 0.8124 0.78 (0.47) 0.0983 0.69 (0.46) 0.132
Clinic
clinical sBP (mmhg) 0.02 (0.01) ,0.0001 0.02 (0.01) ,0.0001
clinical hr (bpm) −0.00 (0.01) 0.9686 0.00 (0.01) 0.7924
Home
Morning sBP (mmhg) 0.11 (0.01) ,0.0001 0.09 (0.01) ,0.0001
Morning hr (bpm) 0.13 (0.02) ,0.0001 0.09 (0.02) ,0.0001
R2=0.0191 R2=0.1397
Abbreviations: BMi, body mass index; bpm, beats per minute; hr, heart rate; R2, multiple regression coefficient of determination; SBP, systolic blood pressure; SD, standard 
deviation; se, standard error.
e-SBP. Figure 2 summarizes the observed BP changes in 
c-SBP and home SBP after 3 months of follow-up.
regression analyses of BPV at baseline 
and after fimasartan treatment can 
identify factors associated with the change 
in BPV (sD) in the clinic and at home
At baseline, simple and multiple regression analyses 
indicated that the SD of c-SBP was independently asso-
ciated with c-SBP (P,0.0001 for both), and the SD 
of m-SBP was independently associated with m-SBP 
(P,0.0001 for both). Both simple and multiple regression 
analyses showed that the SD of m-SBP was independently 
associated with age, female sex, and m-SBP (P=0.0067 
and P=0.0005, P=0.0032 and P,0.0001, P,0.0001 and 
P,0.0001, respectively), but only the simple regression 
analysis showed an association between the SD of m-SBP 
and body mass index (P=0.0246 and P=0.0553, respec-
tively) (Table 4).
Simple and multiple regression analyses (adjusted for 
age, sex, body mass index, and change in mean arterial 
pressure) were performed to elucidate any factors associated 
with reduced BPV in the clinic and at home after 3 months 
of fimasartan treatment. The change in the SD of c-SBP 
was independently associated with the change in c-SBP 
(P,0.0001 and P=0.0268, respectively), and the change 
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Figure 2 Changes in BPV and BP after fimasartan treatment.
Notes: (A) Changes in SD of beat-to-beat BP (BPV) in clinical and home (morning) settings after 3 months of fimasartan treatment. (B) changes in clinical BP and home 
(morning) BP after 3 months of fimasartan treatment.
Abbreviations: BP, blood pressure; BPV, BP variability; c, clinical; m, morning; sBP, systolic blood pressure; sD, standard deviation.
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in the SD of m-SBP was independently associated with the 
change in m-SBP (P,0.0001 and P=0.0258, respectively) 
(Table 5).
Discussion
The major finding of this study was that after 3 months of 
fimasartan treatment, clinical and home BPVs were signifi-
cantly reduced independent of strong BP reduction. These 
results were derived primarily from the general practitioners 
and participants with relatively low-to-moderate hyperten-
sion risk, and thus represent unbiased BP data in a real 
clinical setting.
In our study, clinical BPV is calculated as the SD of three 
consecutive readings on the same patient in the clinic, and 
thus represents beat-to-beat BPV. By contrast, home BPV 
represents day-to-day variability of BP measured by the 
patients themselves at home for 7 consecutive days. BPV is 
thought to result from various intrinsic and extrinsic factors, 
although it is poorly understood. Beat-to-beat variability is 
known to be more strongly influenced by increased central 
sympathetic drive, decreased arterial and cardiopulmonary 
reflex, and humoral, rheological, behavioral, and emotional 
factors.27 Day-to-day variability has been reported to depend 
more strongly on arterial stiffness, improper dosing or titra-
tion of medication, poor medication compliance, and irregu-
larity of self-measurements performed at home.4,27
Clinical BP has been shown to be strongly correlated 
with home BP, but the correlation between clinical BPV and 
home BPV has not been elucidated. Home BP measurement 
is reported to reflect the patient’s true BP because measure-
ments are recorded multiple times throughout the day in a 
comfortable environment. This means that the “white coat 
effect” can be ruled out. Therefore, home BP measurement is 
a better predictor of cardiovascular morbidity and mortality. 
BPV was assessed by home BP measurement in our study. 
The results are supported by demonstrating a relationship 
of day-to-day BPV with cardiovascular outcomes, which 
is independent of mean BP.15,16 The Finn-Home Study 
confirmed this by showing that morning day-to-day BPV is 
a predictor of cardiovascular events after adjusting for age 
and mean home BP.28 Other studies also demonstrated this 
association15,28 and the association with increased risk of 
cardiac, vascular, and renal organ damage.13 The reduction of 
BPV is recognized as a potential target for improved manage-
ment of hypertension to prevent cardiovascular events.
There have been conflicting results regarding the capacity 
of antihypertensive drugs to reduce BPV. In general, calcium 
channel blockers have been reported to reduce BPV, which 
was determined by the SD of 24-hour ambulatory BP,29,30 
and were superior to enalapril in the prevention of coronary 
events in patients with angiographically proven coronary 
artery disease and controlled BP.31 Some ARBs were shown 
to reduce BPV, whereas others did not show any effects. In 
the X-CELLENT study, 3 months of candesartan treatment 
did not show any effect on BPV evaluated by 24-hour BP 
monitoring.30 Valsartan did not significantly change BPV 
in patients with hypertension after 12 months of treatment, 
despite reducing BP.29 In a recent study with home monitoring 
of BP, valsartan increased individual SD of morning SBP, but 
telmisartan did not affect BP after its use as an add-on agent in 
patients on amlodipine monotherapy.32 In an animal study, the 
superiority of telmisartan over valsartan in sustained BP con-
trol and reduction of BPV was attributed to further suppression 
of sympathetic activity and improvement of the baroreceptor 
reflex.33 Based on this evidence, the ARB-mediated reduction 
of BPV might not be due to its classic effects, but instead may 
be due to the effects of its own drug characteristics.
In our study, 3 months of fimasartan treatment significantly 
reduced BP and BPV in the clinic and at home. Although 
the methods of measuring BPV differ, the reductions in SD 
Table 5 Linear regression analyses of factors associated with changes in SD of clinical and morning home SBP after fimasartan 
treatment
Simple regression Multiple regression*
β (SE) P-value β (SE) P-value R2
Changes in SD of clinical SBP
change in clinical sBP (mmhg) 0.03 (0.01) ,0.0001 0.04 (0.02) 0.0268 0.0213
change in clinical hr (bpm) −0.00 (0.01) 0.7058 −0.00 (0.01) 0.7055 0.0179
Changes in SD of morning home SBP
change in morning sBP (mmhg) 0.09 (0.01) ,0.0001 0.08 (0.03) 0.0258 0.0672
change in morning hr (bpm) 0.15 (0.02) ,0.0001 0.08 (0.02) 0.0006 0.0762
Note: *These models are adjusted for age, sex, body mass index, and change in mean arterial pressure (DBP + [sBP−DBP]/3), where DBP is diastolic blood pressure.
Abbreviations: bpm, beats per minute; hr, heart rate; R2, multiple regression coefficient of determination; SBP, systolic blood pressure; SD, standard deviation; SE, standard 
error.
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arBs and blood pressure variability
after fimasartan treatment were similar to the results of the 
X-CELLENT study with amlopidine.30 A reduction in beat-
to-beat variability probably indicates a positive influence on 
its physiological mechanism, which may be attributable to a 
fimasartan-mediated reduction in central sympathetic drive. 
Factors that result in day-to-day variability, including increased 
arterial stiffness, improper dosing or titration of antihypertensive 
medication, and poor medication compliance, cannot be readily 
changed with 3 months of fimasartan treatment. However, we 
clearly observed a reduction in BP after fimasartan treatment, 
indicating better BP control, which in turn might have led to 
better BPV control. Further research is needed to identify the 
pharmacological mechanisms behind these effects.
To the best of our knowledge, the present study provides 
the first prospective evidence that fimasartan stabilizes day-
to-day home systolic BPV. This conclusion was derived from 
data on measurement of BP in real clinical practice and self-
measurement at home, not at a highly selected tertiary center. 
Although this study did not identify the exact mechanism 
of fimasartan-mediated BPV reduction, the efficacy of 
fimasartan to reduce BPV was observed in home BPV inde-
pendent of clinical BPV. The effect of fimasartan on reducing 
home systolic BPV may be related to its positive effects on 
hypertension prognosis shown by recent population-based 
data, which suggest that higher BPV is associated with 
increased all-cause mortality. Therefore, we can presume 
that hypertensive patients with elevated day-to-day BPV 
may benefit from treatment with fimasartan.
Study limitations
This study has some limitations that require consideration. 
First, there is limited information concerning the underlying 
mechanism of BPV reduction. However, reduced mean SBP 
may imply amelioration of autonomic nervous system regula-
tion. Second, the quality of the measurement procedure could 
have affected the BPV data, although the participants were 
instructed to measure BP under relatively controlled condi-
tions. The details of home BP data were blinded until final 
analysis; therefore, information bias was probably not a sig-
nificant contributing factor to the measurement and evaluation 
of home BPV. Third, potential confounding factors of BPV, 
including those related to diet, psychological factors, and drug 
compliance, were not investigated in the present study.
Perspectives
Potential confounding factors of BPV, such as diet, psycho-
logical factors, and drug compliance, should be investigated 
in future studies. Further studies on the change in clinical 
BP, morning BP, and BPV between diabetic and nondiabetic 
patients may be necessary as the findings may provide some 
insight into the mechanism of fimasartan on day-to-day BPV 
(eg, arterial stiffness related to diabetes). Studies on the effects 
of ARBs in different populations (eg, uncontrolled or resistant 
hypertension) will be necessary. Whether the change in BPV 
is dependent on the fimasartan dosage remains to be analyzed. 
Fimasartan may have additional beneficial effects on cardiovas-
cular protection by reducing BPV in addition to significantly 
reducing the mean levels of home BP. Whether reduction 
in BPV translates into long-term clinical benefits, such as 
reduction of all-cause and cardiovascular mortality and target 
organ damage, needs to be investigated in future research. The 
observed superiority of fimasartan over other antihypertensive 
drugs in reducing BPV and preventing cardiovascular events 
warrants further investigation within clinical settings.
Conclusion
The angiotensin receptor antagonist fimasartan is known to 
have a strong antihypertensive effect. However, the effects 
on targets other than BP are unknown. This study evaluated 
whether fimasartan treatment affected clinical and home 
BP variability in addition to reducing BP. Three months of 
fimasartan treatment reduced day-to-day BP variability inde-
pendent of BP reduction in patients with mild-to-moderate 
hypertension. The results suggest that fimasartan attenuates 
BP fluctua tions and provides better control of hypertension. 
Fimasartan treatment also significantly reduced day-to-day 
BP variability at home independent of BP reduction, which 
may provide an additional benefit for prevention of cardio-
vascular events.
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